{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:46:55Z","timestamp":1786373215231,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Cardiorenal syndromes (CRSs) with bidirectional heart-kidney signaling are increasingly being recognized for their association with increased morbidity and mortality. In acute CRS, recognition of the importance of worsening kidney function complicating management of acute decompensated heart failure has led to the examination of this specific outcome in the context of acute heart failure clinical trials. In particular, the role of fluid overload and venous congestion has focused interest in the most effective use of diuretic therapy to relieve symptoms of heart failure while at the same time preserving kidney function. Additionally, many novel vasoactive therapies have been studied in recent years with the hopes of augmenting cardiac function, improving symptoms and patient outcomes, while maintaining or improving kidney function. Similarly, recent advances in our understanding of the pathophysiology of chronic CRS have led to reanalysis of kidney outcomes in pivotal trials in chronic congestive heart failure, and newer trials are including changes in kidney function as well as kidney injury biomarkers as prospectively monitored and adjudicated outcomes. This paper provides an overview of some new developments in the pharmacologic management of acute and chronic CRS, examines several reports that illustrate a key management principle for each subtype, and discusses opportunities for future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.02920313","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T02:15:25Z","timestamp":1376014525000},"page":"1808-1815","source":"Crossref","is-referenced-by-count":20,"title":["Cardiorenal Syndrome"],"prefix":"10.2215","volume":"8","author":[{"given":"Andrew A.","family":"House","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20230811","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/gfq136","article-title":"Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference","volume":"25","author":"House","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R2-25-20230811","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R3-25-20230811","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"R4-25-20230811","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"R5-25-20230811","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: Systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J Card Fail"},{"key":"R6-25-20230811","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.amjcard.2007.12.014","article-title":"Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions","volume":"101","author":"Sweitzer","year":"2008","journal-title":"Am J Cardiol"},{"key":"R7-25-20230811","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ejheart.2007.05.010","article-title":"Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction","volume":"9","author":"Damman","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"R8-25-20230811","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2007.09.043","article-title":"Elevated intra-abdominal pressure in acute decompensated heart failure: A potential contributor to worsening renal function?","volume":"51","author":"Mullens","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R9-25-20230811","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/eurjhf\/hfs209","article-title":"Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: The importance of blood pressure reduction during treatment","volume":"15","author":"Dupont","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"R10-25-20230811","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/j.ajkd.2010.04.012","article-title":"Therapeutic strategies for heart failure in cardiorenal syndromes","volume":"56","author":"House","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R11-25-20230811","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1055\/s-0028-1112283","article-title":"Experimental studies and clinical trials of a new diuretic","volume":"88","author":"Kleinfelder","year":"1963","journal-title":"Dtsch Med Wochenschr"},{"key":"R12-25-20230811","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0735-1097(01)01479-6","article-title":"Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure","volume":"38","author":"Marenzi","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R13-25-20230811","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","article-title":"Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival","volume":"122","author":"Testani","year":"2010","journal-title":"Circulation"},{"key":"R14-25-20230811","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-25-20230811","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"367","author":"Bart","year":"2012","journal-title":"N Engl J Med"},{"key":"R16-25-20230811","first-page":"R97","article-title":"Atrial natriuretic factor modulates whole kidney tubuloglomerular feedback","volume":"259","author":"Margulies","year":"1990","journal-title":"Am J Physiol"},{"key":"R17-25-20230811","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2362.2006.01689.x","article-title":"Role of endothelin and endothelin receptor antagonists in renal disease","volume":"36","author":"Neuhofer","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"R18-25-20230811","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejheart.2008.01.010","article-title":"Adenosine and kidney function: Potential implications in patients with heart failure","volume":"10","author":"Vallon","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"R19-25-20230811","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.bjp.0707516","article-title":"The endothelin system as a therapeutic target in cardiovascular disease: Great expectations or bleak house?","volume":"153","author":"Kirkby","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R20-25-20230811","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1388-9842(01)00210-0","article-title":"Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology\u2014WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME","volume":"3","author":"Coletta","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"R21-25-20230811","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"R22-25-20230811","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jacc.2010.11.057","article-title":"Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function)","volume":"57","author":"Voors","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R23-25-20230811","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"R24-25-20230811","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"R25-25-20230811","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"R26-25-20230811","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/CCM.0b013e318232962a","article-title":"Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies","volume":"40","author":"Landoni","year":"2012","journal-title":"Crit Care Med"},{"key":"R27-25-20230811","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"R28-25-20230811","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10557-007-6066-7","article-title":"Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine","volume":"21","author":"Yilmaz","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"R29-25-20230811","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"R30-25-20230811","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R31-25-20230811","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMe1014162","article-title":"Comparative effectiveness of diuretic regimens","volume":"364","author":"Fonarow","year":"2011","journal-title":"N Engl J Med"},{"key":"R32-25-20230811","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1161\/CIRCULATIONAHA.111.064097","article-title":"Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation","volume":"125","author":"Rafiq","year":"2012","journal-title":"Circulation"},{"key":"R33-25-20230811","doi-asserted-by":"crossref","first-page":"425923","DOI":"10.4061\/2011\/425923","article-title":"Heart-kidney biomarkers in patients undergoing cardiac stress testing","volume":"2011","author":"Haapio","year":"2011","journal-title":"Int J Nephrol"},{"key":"R34-25-20230811","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.2169\/internalmedicine.50.5925","article-title":"Deterioration of renal function by chronic heart failure is associated with congestion and oxidative stress in the tubulointerstitium","volume":"50","author":"Tanaka","year":"2011","journal-title":"Intern Med"},{"key":"R36-25-20230811","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9149(92)91194-9","article-title":"Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial)","volume":"70","author":"Ljungman","year":"1992","journal-title":"Am J Cardiol"},{"key":"R38-25-20230811","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-8703(99)70009-8","article-title":"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the studies of left ventricular dysfunction (SOLVD)","volume":"138","author":"Knight","year":"1999","journal-title":"Am Heart J"},{"key":"R39-25-20230811","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2005030270","article-title":"Kidney function and mortality among patients with left ventricular systolic dysfunction","volume":"17","author":"Khan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R40-25-20230811","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0195-668X(02)00526-2","article-title":"Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: The CATS randomized trial","volume":"24","author":"Hillege","year":"2003","journal-title":"Eur Heart J"},{"key":"R41-25-20230811","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"R42-25-20230811","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"R43-25-20230811","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201310000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:36Z","timestamp":1786369416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201310000-00025"}},"subtitle":["New Developments in the Understanding and Pharmacologic Management"],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02920313","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}